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Epstein-Barr virus (EBV) latent membrane protein 1 (LMP-1) is required for EBV immortalization of primary B cells in vitro. Signal
transducers and activators of transcription (STATs) play a pivotal role in the initiation and maintenance of certain cancers. STAT proteins,
especially STAT-1, -3, and -5, are persistently tyrosine phosphorylated or activated in many cancers. We show here that EBV-infected type III
latency cells, in which the EBVoncoprotein, LMP-1 is expressed, express high levels of four STATs (STAT-1, -2, -3, and -5A) and that LMP-1
is responsible for the induction of three (STAT-1, -2, and -3). In addition, the C-terminal activator region 1 (CTAR-1) and CTAR-2 of LMP-1
cooperatively induced the expression of STAT-1. The cooperativity was evident when CTAR-1 and CTAR-2 were present in cis, but not in
trans. Furthermore, NF-nB is an essential factor involved in the induction of STAT-1. Most of the induced STATs were not phosphorylated at
the critical tyrosine residue activated by many cytokines. However, the induced STATs, at least STAT-1, were functional because it could be
activated by interferon (IFN) and could upregulate an IFN-inducible gene. Finally, expression of STAT-1, but not STAT-2 and -3, is associated
with EBV transformation. The association of the expression of STAT-1, -2, -3, and -5Awith EBV type III latency and the expression of STAT-1
in the EBV transformation process may be part of the viral programming that regulates viral latency and cellular transformation.
D 2004 Elsevier Inc. All rights reserved.Keywords: LMP-1; STAT-1; Epstein-Barr virus; Latency
Introduction Thebiologic hallmark of theEBV–lymphocyte interaction isEpstein-Barr virus (EBV) is a human herpesvirus of
increasing medical importance. EBV infection is associated
with the development of nasopharyngeal carcinoma (NPC)
and Burkitt’s lymphoma (BL). In addition, EBV infection is
an important cause of lymphomas in severely immunocom-
promised persons, especially patients with AIDS and organ-
transplant recipients (Kieff, 1996; Pagano, 1991, 1999;
Raab-Traub, 1996; Rickinson and Kieff, 1996).0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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joseph_pagano@med.unc.edu (J.S. Pagano).latency. Three types of latency have been described, each having
its own distinct pattern of gene expression. Type I latency is
exemplified by BL tumors in vivo and earlier passages of
cultured cell lines derived from BL biopsies. EBNA1 is the
major viral protein synthesized in this form of latency. Latent
membrane protein 2A (LMP2A)may also be expressed. Type II
latency is exemplified by NPC and Hodgkin’s disease. EBNA1,
LMP-1, LMP2A, and LMP2B proteins are expressed in type II
latency. Type III latency is typical of early phases of EBV
lymphoproliferative syndromes and is captured in lymphoblas-
toid cell lines (LCLs). Nine viral proteins are expressed,
including all six nuclear proteins (EBNA-1, EBNA-2, EBNA-
3A, EBNA-3B, EBNA-3C, and EBNA-LP) and the three
integral membrane proteins (LMP-1, LMP-2A, and LMP-2B)
(reviewed in Kieff, 1996; Rickinson and Kieff, 1996).
EBV immortalizes and transforms B cells from cord and
adult blood into LCLs and concomitantly establishes type III
L. Zhang et al. / Virology 323 (2004) 141–152142latency in vitro. LMP-1 expression is required for the immor-
talization process (Kaye et al., 1993;Kilger et al., 1998). LMP-1
can induce a variety of cellular genes that enhance cell survival
as well as adhesive, invasive, and angiogenic potential (Fries et
al., 1996; Henderson et al., 1991; Miller et al., 1995; Murono et
al., 2001; Wakasaka and Pagano, 2003; Wakasaka et al., 2002,
2004; Wang et al., 1985, 1990a; Yoshizaki et al., 1998).
LMP-1 is an integral membrane protein with six transmem-
brane-spanning domains and aC-terminal domain located in the
cytoplasm (Kieff, 1996; Liebowitz et al., 1986). LMP-1 acts as a
constitutively active receptor-like molecule that does not need a
ligand (Gires et al., 1997). The transmembrane domains medi-
ate oligomerization of LMP-1 molecules in the plasma mem-
brane, a prerequisite for LMP-1 function (Floettmann et al.,
1996; Gires et al., 1997). Two regions in its C terminus initiate
signaling processes, the C-terminal activator region 1 (CTAR-1,
amino acids 194–231) and CTAR-2 (amino acids 332–386)
(Fig. 1; and Huen et al., 1995; Mitchell and Sugden, 1995).
CTAR-1 is a contributor to the activation of nuclear factor
nB (NF-nB) by LMP-1. The PXQXT motif localized withinFig. 1. Molecular structure and locations of functional domains in LMP-1.
LMP-1 contains a short cytoplasmic amino terminus, a transmembrane
hydrophobic domain, and a long cytoplasmic carboxy terminus that
contains three major signaling domains. CTAR-1 mediates interaction with
the TRAFs, and is the minor NF-nB-activating region. The location of the
TRAF-interacting motif, PXQXT, is indicated. CTAR-2 is the major NF-
nB-activating region. Also, CTAR-2 can activate JNK and p38 molecules.
Two JAK3-binding sites are also indicated; the JAK-STAT pathway might
be activated by interaction between JAK3 and LMP-1. The amino acid
numbers are shown. The drawing is not on scale.CTAR-1 is involved in the interaction with tumor necrosis
factor receptor (TNFR)-associated factors (TRAFs). TRAF-1,
-2, -3, and -5 associate with LMP-1 with different affinities
and are responsible for NF-nB activation by CTAR-1
(Devergne et al., 1996, 1998; Miller et al., 1997; Sandberg
et al., 1997). CTAR-1 is responsible for induction of epidermal
growth factor receptor (EGFR) and TRAF-1 (Devergne et al.,
1998; Miller et al., 1997). CTAR-1 is required for the
transformation of B cells by EBV, and the PXQXT motif is
essential for this process (Izumi et al., 1997; Kaye et al., 1999).
CTAR-2 is also a contributor to the activation of NF-nB
by LMP-1. CTAR-2, through its interaction with TNFR-
associated death domain protein (TRADD), activates NF-
nB (Izumi and Kieff, 1997; Izumi et al., 1999). Also, c-jun
N-terminal kinase (JNK) and p38 are activated by CTAR-2
(Eliopoulos and Young, 1998; Eliopoulos et al., 1999;
Kieser et al., 1997). The final three amino acids (YYD)
play an essential role in the signal transduction pathways of
CTAR-2.
Interestingly, consensus janus kinase 3 (JAK3) binding
sites between CTAR-1 and CTAR-2 have been identified
(Fig. 1). However, whether JAK3 can bind to these sites and
is responsible for the activation of signal transducer and
activator of transcription 1 (STAT-1) or other STATs is
controversial (Brennan et al., 2001; Fielding et al., 2001;
Gires et al., 1999; Higuchi et al., 2002).
STATs are a family of latent transcription factors that
become activated by phosphorylation on a single tyrosine,
typically in response to extracellular ligands (Darnell et al.,
1994; Stark, 1997). Virtually every cytokine and growth
factor can cause STAT phosphorylation through receptor or
associated kinases. Once phosphorylated, STATs can form
homo- or heterodimers that accumulate in the nucleus,
recognize specific DNA sequences, and activate transcription
(Darnell et al., 1994; Stark, 1997).
In this report, the relation between EBV and STATs is
examined. We show that high levels of expression of STAT-
1, -2, -3, and -5A are associated with EBV type III latency
in which LMP-1 is expressed. LMP-1 stimulates the ex-
pression of STAT-1, -2, and -3, but not STAT-5A. Interest-
ingly, the maximum induction of STAT-1 is a result of a
cooperative interaction between the LMP-1 CTAR-1 and
CTAR-2 domains. However, after induction by LMP-1,
STAT-1 is not activated by phosphorylation. Induction of
STATs, especially STAT-1, -3, and -5A, by EBV may be
relevant to viral transformation processes as well as the
pathogenesis of EBV-associated tumors.Results
Expression of STAT-1 is correlated with LMP-1 protein in
type III latency
We first scanned the expression pattern of STAT-1 in
various EBV-infected cell lines with type I or type III
Fig. 3. LMP-1 induces the expression of STAT-1 protein. Lysates from cells
transfected with pcDNA3 (lanes 1 and 3) or LMP-1 expression plasmid
(lanes 2 and 4), or EBNA2 expression plasmid (lane 5) were used. Western
blots with STAT-1, LMP-1, EBNA-2, and tubulin antibodies were
performed. Lanes 1 and 2, Akata cells were used for transfection; lanes
3–5, DG75 cells used. The identity of proteins is as shown.
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derived from a single parental cell line. The paired lines
differ only in their types of latency (Nonkwelo et al., 1996;
Zhang and Pagano, 1997). The Jijoye (type III) cell line has
all the latency genes in its viral genome, whereas its
derivative, the P3HR1 line, lacks the EBNA-2 gene and a
portion of EBNA-LP (Adldinger et al., 1985). As a result of
the deletion, P3HR1 cells do not express EBNA-2, and
consequently because EBNA-2 transactivates the LMP-1
promoter (Abbot et al., 1990; Ghosh and Kieff, 1990; Tsang
et al., 1991; Wang et al., 1990b), express a very low level of
LMP-1 apparently through induction by IRF-7 (Ning et al.,
2003). BL41-P3HR1 and BL41-B95-8 are converted by
infection of EBV-negative BL41 cells with either P3HR1
or B95-8 virus, respectively (Calender et al., 1987). In
addition to these paired cell lines, other available EBV
latently infected cell lines were also examined. As shown
in Fig. 2, STAT-1 protein was expressed at high levels in
type III cell lines with high levels of LMP-1. In type I cells
in which LMP-1 is not expressed, STAT-1 was expressed at
much lower levels. These data indicate that the expression
of STAT-1 correlated with the expression of LMP-1 in type
III latency.
LMP-1 stimulates the expression of STAT-1 protein
Because EBNA-2 is the primary inducer of LMP-1mRNA
(Abbot et al., 1990; Ghosh and Kieff, 1990; Tsang et al.,
1991; Wang et al., 1990b), and because of the consistent
association between STAT-1 and LMP-1 expression (Fig. 2),
it is possible that either EBNA-2 and/or LMP-1 are respon-
sible for the induction of STAT-1. Both EBV-negative DG75
and EBV-positive Akata cells were used to determine which
viral gene could directly induce the expression of STAT-1.
LMP-1 or EBNA-2 and a CD4-expression plasmid were
transfected into cells, and the levels of STAT-1 were deter-
mined by Western blotting after selection of the transfected
cells by the use of CD-4 antibody-conjugated magnetic beads
(see Materials and methods). As shown in Fig. 3, LMP-1
expression causes a marked increase in STAT-1 proteinFig. 2. High expression levels of STAT-1 are associated with the expression of LMP
8% SDS-PAGE and stained with Ponceau S Red after transfer of protein to the me
performed simultaneously. The names of cell lines are as labeled. SAV I and SAVlevels in both DG75 and Akata cells; however, EBNA-2
seems to have no effect on the induction of STAT-1 in
DG75 cells. Therefore, LMP-1 is probably responsible for
the induction of STAT-1 in type III latency cells. If
EBNA2 is involved in the induction of STATs, it is likely
to do so indirectly via induction of LMP-1 in EBV-
infected cells.
LMP-1 induces the expression of STAT-1, STAT-2, and
STAT-3
Whether LMP-1 increases STAT-1 at the RNA level was
examined by RNase Protection Assays (RPA) with specific
probes. The probe set is capable of detecting RNA of all
STATs (see Materials and methods for details). Pairs of the
genetically identical Sav I and Sav III cell lines, as well as
P3HR1 cells and its parental line, Jijoye, were used for the
experiments. As shown in Fig. 4, STAT-1 RNA levels were-1. Equal amounts of protein lysates from cell lines were electrophoresed in
mbrane. Western blotting with STAT-1, LMP-1, and tubulin antibodies was
III are genetically identical cell lines derived from the same parental line.
Fig. 4. LMP-1 induces the expression of endogenous STAT-1, -2, and -3. (A) LMP-1 induces the expression of endogenous STAT-1, -2, and -3 RNA. Human
STAT RPA probes were labeled with a-32P-UTP and used for RPA. Lane 11, undigested STATs probes; lanes 1, 2, 6, and 7, RNAs from P3HR1, Jijoye, Sav I
and Sav III cells, respectively; lane 8, yeast tRNA; lane 5, blank. Lanes 3, 4, 9, and 10, RNAs from transfected and concentrated Akata cells; lanes 3 and 9,
pcDNA3; lanes 4 and 10, LMP-1 expression plasmid. The identity of the STATs is as indicated. (B) The relative levels of STAT RNAs induced by LMP-1. The
autoradiography was examined by the Gene Genius Bioimaging System, and the intensity of bands was recorded and analyzed. The results from three
independent experiments (two of which are shown in lanes 3, 4, 9, and 10 in panel A) were used for calculations of the induction. STAT-6 was used as an
internal control. The relative levels of STAT-1, -2, -3, and standard deviations are shown. (C) LMP-1 induces the expression of endogenous STAT-2 and -3
proteins. Cell lysates from transfected and concentrated Akata cells were used for Western blot analysis. The identity of proteins is as shown.
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STAT-1 RNA expression is also associated with LMP-1
expression, in agreement with the data in Fig. 2. Surprising-
ly, in addition to STAT-1, expression levels of STAT-2, -3,
and -5A RNAs were also higher in type III latency cells
(lanes 1, 2, 6, and 7). STAT-1, -2, -3, and -5A RNAs were
also expressed at higher levels in CBC/B95-8 (an LCL, type
III latency, with high level expression of LMP-1) and lower
in Eli-BL (type I latency, no LMP-1 expression) (data notshown). Thus, the expression of STAT-2, -3, and -5A RNAs
is also associated with type III latency.
Whether LMP-1 increases STAT RNAs was examined by
transient transfection of LMP-1 and a CD4-expression
plasmid into Akata cells and selecting transfected cells as
before. As shown in Fig. 4, LMP-1 expression produces
increased levels of STAT-1, -2, and -3 RNAs; duplicate
results are shown in lanes 3 and 4, and lanes 9 and 10.
However, LMP-1 did not increase the expression of STAT-
Fig. 5. Cooperativity between both CTARs is required for efficient
induction of STAT-1. (A) Schematic diagram of LMP-1 and its mutants.
Solid ovals, CTAR1 PXQXT motif; solid bars, CTAR-2 YYD motif. X
denotes the destruction of the motifs. LMP-PQAA has mutations in the
conserved PXQXT motif that change the proline and glutamine into
alanines. LMP-IID has mutations in the CTAR-2 YYD motif that change
the two tyrosines into isoleucines. LMP-DM has mutations in both CTAR-1
and CTAR-2. (B) Akata cells were transfected with pcDNA-3 vector or the
various LMP-1 plasmids shown in A. The cell lysates were used for
Western blot analysis. The identity of the proteins is indicated.
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levels are shown in Fig. 4B. In addition, we tested if LMP-1
could induce the expression of STAT-2 and -3 proteins. In
Akata cells, both STAT-2 and -3 are induced by the
expression of LMP-1 as shown in Fig. 4C. In DG75 cells,
STAT-2 protein was also efficiently induced; however, the
induction of STAT-3 protein was not very obvious (data not
shown). The data together indicate that LMP-1 increases the
expression of STAT-1, -2, and -3, but not STAT-5A.
CTAR-1 and CTAR-2 cooperatively induce the expression of
STAT-1
Next, the LMP-1 domain requirement for the induction
of STAT-1 was examined in Akata cells by the use of several
LMP-1 mutants. Akata cells were used for these experi-
ments because STAT-1 is highly inducible in this cell line
(Figs. 3 and 4). We tested the role of CTARs in the induction
of STAT-1 in the context of the whole LMP-1 molecule.
LMP-PQAA has mutations in CTAR1 PXQXT motif that
change the proline and glutamine into alanines. PQAA
mutation in intact LMP-1 will knock out the function of
the TRAF-interaction domain (Devergne et al., 1998; Miller
et al., 1998; Sandberg et al., 1997). LMP-IID has mutations
in the CTAR-2 YYD motif that change the two tyrosines
into isoleucines. The tyrosines (Y) in the last three amino
acids of LMP-1 (YYD) have been shown to play an
important role in the signaling pathway of CTAR2; muta-
tions of the tyrosine amino acids abolish TRADD binding
and the activation of NF-nB and AP-1 by the CTAR-2
region (Floettmann and Rowe, 1997; Izumi et al., 1999;
Kieser et al., 1997). LMP-DM has mutations in both CTARs
(Fig. 5A). As shown in Fig. 5B, LMP-PQAA or LMP-IID
induces very marginal levels of STAT-1. When both CTARs
were mutated in LMP-DM, STAT-1 induction is completely
abolished. Because either CTAR alone only marginally
induces STAT-1, these data suggest that CTAR1 and CTAR2
cooperatively induce the expression of STAT-1.
Whether the full induction of STAT-1 can be comple-
mented in trans was examined by co-transfection of indi-
vidually mutated CTAR-1 and CTAR-2 mutants. As shown
in Fig. 5B, co-transfection of LMP-1 plasmids containing
individually mutated CTAR-1 (LMP-PQAA) and CTAR-2
(LMP-IID) barely induces STAT-1 and certainly not at a
level comparable to that induced by LMP-1wt. These data
suggest that CTAR1 and CTAR-2 cooperatively induce
STAT-1 only in cis configuration, but not in trans.
NF-jB is essential for the induction of STAT-1 by LMP-1
Next, the roles of intracellular molecules involved in the
induction were examined. Both CTARs can activate NF-nB
as shown in Fig. 6B. In addition, several other molecules
have been shown to be activated by LMP-1. As shown in
Fig. 6A, LMP-1 alone induced high levels of STAT-1 in
either Akata or DG75 cells. However, in the presence ofsuperrepressor InB (sr-InB), the expression of STAT-1 was
completely abolished. Surprisingly, dominant-negative
mutants for TRAFs (TRAF-1, -2, -3, and -5 DNs) were
not able to block the induction of STAT-1 efficiently even
though the level of LMP-1 expressed was similar. In
addition, AP-1DN and JAK3DN were not able to block
the induction (data not shown).
Because NF-nB is essential for the induction of STAT-1,
and both CTARs are capable of activating NF-nB, we asked
whether NF-nB activation might be contributing to the
cooperative induction of STAT-1 by CTAR-1 and -2. As
shown in Fig. 6B, the two CTAR mutations could activate
NF-nB individually as predicted, and the combination of the
two was able to activate NF-nB to a similar level as wild-
type LMP-1. These data are in contrast to the requirement
for the cis configuration of the CTARs for the induction of
STAT-1 and suggest that other factors in addition to NF-nB
are also involved.
Phosphorylation of Tyrosine 701 in STAT-1 is not detected
in EBV latency
STAT-1, -3, and -5 are often activated in human cancers.
Phosphorylation at the critical Tyr-701 residue of STAT-1 is
a crucial event for its function although the role of activated
STAT-1 in oncogenesis is not clear yet. We tested the
activation status of STAT-1 by the use of phospho-specific
Fig. 6. NF-nB is required for the induction of STAT-1. (A) NF-nB is required for the induction of STAT-1. Akata or DG75 cells were transfected with pcDNA-3
vector or LMP-1, or LMP-1 plus sr-InB, or LMP-1 plus a combination of dominant-negative mutants of TRAF-1, -2, -3, and -5 (TRAF DNs). The cell lysates
were used for Western blot analysis. The identity of proteins is as shown. (B) LMP-1 activates NF-nB activity in Akata cells. Akata cells were transfected with
NF-nB-reporter construct along with pcDNA-3 or various LMP-1 expression plasmids. Luciferase activities were normalized by h-galactosidase activity. The
reporter activity is expressed relative to vector control. Standard deviations are shown.
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lated, or very marginally activated, at the critical Tyr-701
residue in all the EBV-positive cell lines tested including
Akata, Jijoye, and Sav III (lanes 1 and 3, and data not
shown). However, STAT-1 in these cells is capable of being
phosphorylated in response to IFN-a, suggesting that the
STAT-1 is functional (lanes 2 and 4). We also tested the
phosphorylation status of serine 727 (Ser-727). Interesting-
ly, the STAT-1 Ser-727 is apparently constitutively phos-
phorylated (lanes 5–8). Because Ser-727 is also phosphor-
ylated in type I latency cells (data not shown), the results
suggest that the phosphorylation of Ser-727 is independent
of LMP-1. In addition, the subcellular localization of STAT-1
was examined by immunostaining in Jijoye cells, in which
STAT-1 is highly expressed (Fig. 2). Without IFN treatment,
STAT-1 predominantly localized in the cytoplasm; however,
STAT-1 was predominantly localized to the nucleus upon
IFN treatment as predicted (data not shown). It is noteworthy
that we did not observe any phosphorylation and nuclear
translocation of STAT-1 in LMP-1-transfected human B cells
(data not shown).
In addition to phosphorylation of the tyrosine residue,
IFN can induce its target genes. As shown in Fig. 7B,interferon-stimulated gene 15 (ISG-15) could be induced in
all four cell lines tested. All these results suggest that STAT-
1 in type III latency cells is not activated, or very marginally
activated, at the critical tyrosine residue (Tyr-701). Howev-
er, the induced STAT-1 is functional and capable of respond-
ing to IFN.
We also determined the activation status of STAT-3 and -5,
both of which are associated with human cancers. Phospho-
STAT-3-specific or phospho-STAT-5-specific antibodies
were used to determine the activation status of STAT-3 and
-5. Neither STAT was phosphorylated, or phosphorylated at
very low levels in type III latency cells. However, STAT-3
and -5 could be activated by IL-6 (for STAT-3) or IL-2 (for
STAT-5) (data not shown). These data on the activation status
of STAT-3 and -5 are in agreement with a recent report
(Higuchi et al., 2002).
Expression of STAT-1 is associated with EBV transformation
STATs are involved in the pathogenesis of human can-
cers. STATs, especially STAT-1, -3, and -5, are persistently
tyrosine phosphorylated or activated and play a pivotal role
in initiation and maintenance of the phenotypes of some
Fig. 7. Activation status of STAT-1 in EBV-infected cells. (A) Phosphory-
lation status of STAT-1 in type III latent cells. Western blot with phospho-
specific STAT-1 antibodies was first performed. The membranes were then
stripped and antibody against intact STAT-1 was used to determine the total
STAT-1 expression. Lanes 2, 5, 6, and 8 are lysates of cells that had been
treated with IFN-a for 30 min. Lanes 1, 3, 5, and 7 are untreated lysates. Cell
lines are labeled at the top. (B) ISG-15 is inducible in latent cells. Lysates
from cells treated with IFN-a (12 h) were used. Western blots with ISG-15
and tubulin antibodies were performed. The identity of proteins is as shown.
Fig. 8. Expression of STAT-1 is associated with EBV transformation
processes. (A) STAT-1 expression is induced during the process of
immortalization of B lymphocytes by EBV. Primary B cells were isolated
from fresh blood. Equal amounts of protein lysates from primary B cells
and four newly transformed LCLs were electrophoresed, and Western
blotting with various antibodies was performed. The identity of proteins is
indicated. (B) STAT-1 is not phosphorylated at a critical tyrosine residue
during EBV transformation. Western blot with phospho-specific (Tyr-701)
STAT-1 antibodies was first performed. The membranes were then stripped,
and antibodies against total STAT-1, LMP-1, and tubulin were used to
determine expression of these proteins. The positive control is Jijoye cells
treated with IFN-a for 30 min. The identity of proteins is as shown.
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and Darnell, 2000).
EBV can immortalize and transform primary B cells into
continually growing lymphoblastoid cell lines (LCLs). We
examined if STATs are associated with this immortalization/
transformation process. The primary B cells were isolated
from fresh blood by CD-19-conjugated magnetic beads (see
Materials and methods for details). Primary B cells from two
individuals were compared with four newly transformed
LCLs. As shown in Fig. 8, the expression of STAT-1 is
associated with the EBV immortalization/transformation
process. Interestingly, expression of STAT-2, -3, and -5A is
apparently not associated with this process (Fig. 8A). Al-
though we have shown clearly that LMP-1 induces STAT-2
and -3, CD-19-positive primary B cells are heterogeneous
and therefore differ from the clonal type I latency and EBV-
negative Burkitt’s lymphoma cell lines. In addition, it has
been documented that at least one LMP-1-induced gene, Bcl-
2, is not associated with EBV transformation (Henderson et
al., 1991; Martin et al., 1993), and we confirmed this
observation (Fig. 8A). Thus, STAT-1 is the only one identi-
fied that is associated with EBV transformation.
Next, we examined if the phosphorylation of STATs is
associated with EBV transformation processes. Because of
the availability of phospho-STAT antibodies, the phosphor-
ylation status of STAT-1, -3, and -5 were examined by
L. Zhang et al. / Virology 323 (2004) 141–152148Western blot analysis. As shown in Fig. 8B, STAT-1 was not
phosphorylated at the critical Tyr-701 residue. STAT-3 and -5
were not activated either (data not shown), in agreement with
the recent report (Higuchi et al., 2002).Discussion
EBV has the capability of deregulating B-cell growth
through activation of endogenous programs of cellular gene
expression. We show that high levels of STAT-1, -2, -3, and
-5A are associated with EBV type III latency cells. In
addition, LMP-1, a key type III latency gene, could induce
the expression of STAT-1, -2 and -3; however, it could not
induce the expression of STAT-5A RNA (Fig. 4).
Some genes can be induced by both LMP-1 CTARs,
especially those that are regulated primarily by NF-nB
(Mehl et al., 2001; Miller et al., 1997; Takeshita et al.,
1999). In this report, we have shown a cooperative induc-
tion of STAT-1 by the two CTARs in the cis configuration
(Fig. 5B). The requirement for efficient induction of STAT-1
by both CTARs in cis (Fig. 5) is interesting and suggests
that LMP-1 in vivo might assume a functional conformation
maintained by both CTARs. The cooperativity is apparently
not due to the activation of NF-nB because activation of
NF-nB by the CTARs was not cooperative in the same cells
(Fig. 6B). However, NF-nB is an essential factor for the
induction of STAT-1 (Fig. 6). It is obvious that another
factor(s) resulting from the cooperation of the two CTARs is
also involved in the induction of STAT-1. It is somewhat
surprising that the combination of TRAF DNs including
TRAF-1,-2, -3, and -5 could not efficiently block the
induction of STAT-1 (Fig. 6A). Because CTAR-1 is appar-
ently involved in the activation (Fig. 5B), the results also
suggest that another TRAF member(s), or signaling path-
way(s) derived from the TRAF binding domain might be
responsible for partial induction of STAT-1.
LMP-1 has been reported to activate STAT-1 protein by
phosphorylation via JAK-3 based mainly on studies carried
out in a fibroblast cell line (Gires et al., 1999). However, we
examined the STAT-1 and LMP-1 in native environments in
B cells and found that STAT-1 was not phosphorylated in
any of the type III cell lines in which both LMP-1 and
STAT-1 are highly expressed. Also, we did not observe any
phosphorylation and nuclear translocation of STAT-1 by
transfecting LMP-1 into human B cells (data not shown).
The difference might be due to the cell lines used for the
experiments. Activation of JAK-3 by LMP-1 might be due
to the particular cell line used (Higuchi et al., 2002).
Although STATs are mostly in their latent form in EBV
latency, these STATs may also have functional roles. Awell-
studied example is the ability of latent STAT-1 to regulate
osteoblast differentiation by attenuating Runx2, an essential
transcriptional factor in this differentiation process, in the
cytoplasm (Kim et al., 2003). Another example is low-
molecular weight protein 2 (LMP-2) that is involved inMHC class 1 processing. Latent nonphosphorylated STAT-1
is able to move into the nucleus, bind to DNA, and is
responsible for the constitutive expression of LMP-2 (Chat-
terjee-Kishore et al., 2000). Also, LMP-1 has been reported
to activate a STAT-responsive element (Fielding et al., 2001;
Richardson et al., 2003); the induction of STAT-1, -2, and -3
could possibly explain that observation (Fig. 4).
In addition, high expression levels of STATs might be
related to the regulation of the EBV BamHI Q latency
promoter (Qp) which is used for the transcription of
EBNA-1 in type I latency. Activation of the JAK-STAT
pathway has been reported to activate EBV Qp (Chen et al.,
1999, 2003). Because Qp is completely inactive in type III
latency, and STAT-1, -2, -3, and -5A are highly expressed in
type III latency, it is unlikely that any of these STATs
function to activate the promoter. Also LMP-1, which is
expressed in type III latency, represses the activity of Qp
reporter constructs as well as endogenous Qp activity
(Zhang and Pagano, 2000, 2001; Zhang et al., 2001).
Therefore, STAT-1, -2, -3, and -5A are likely to be repress-
ors of Qp in type III latency. In addition, these STATs are
not activated in type I latency in which Qp is active (data not
shown). These observations led us to test the role of STATs
in the regulation of Qp. However, STAT-1, -2, and -3, at
least in their nonphosphorylated state, neither activate nor
significantly repress Qp in Akata cells (data not shown). It is
possible that the activation of Qp by STATs might only be
observable in NPC cells (Chen et al., 2003). Thus, our data
and published reports suggest that the induced but still latent
STATs might be mediators that regulate both cellular and
EBV genes to the benefit of viral latency. However, the
specific targets of these latent STATs are currently unknown.
One of the chief functions of activated STATs is their
involvement in the pathogenesis of human cancers. In
normal cells and in animals, ligand-dependent activation
of the STATs is a transient process, lasting for several
minutes to several hours. In contrast, in many cancerous
cell lines and tumors, where growth-factor dysregulation is
frequent, STAT proteins, especially STAT-1, -3, and -5, are
persistently tyrosine-phosphorylated or activated. These
activated STAT proteins play a pivotal role in initiation
and maintenance of the phenotypes of some cancers (for a
review, see Bowman et al., 2000; Bromberg and Darnell,
2000). We have shown in this report that expression of
STAT-1 is associated with the EBV-transformation process;
however, STAT-2, -3, and -5A are not apparently associated
with immortalization of lymphocytes into cell lines (Fig. 8).
It is also reported that Bcl-2, another LMP-1-inducible gene,
is not associated with the EBV transformation (Henderson
et al., 1991; Martin et al., 1993). Thus, it is apparent that not
all LMP-1-inducible genes are associated with EBV trans-
formation. We suggest that induction of STATs, especially
STAT-1, by LMP-1 may be a part of the EBV programming
that regulates viral latency and leads to cellular transforma-
tion. The overexpression of STAT-1 in EBV transformation
may provide a unique scenario that differs from other
L. Zhang et al. / Virology 323 (2004) 141–152 149cancers in which the tyrosine-phosphorylated STATs are
major factors in oncogenesis. The function of STAT-1 in
EBV transformation is currently under investigation. Also
interesting is that type III latency cells express high levels of
two interferon regulatory factors (IRF-2 and IRF-7) (Zhang
and Pagano, 1997, 1999). It is well known that IRFs are
involved in the regulation of IFN responsiveness (Nguyen et
al., 1997; Pitha et al., 1998; Taniguchi et al., 2001). Thus, it
is likely that EBV regulates its latency state by the use of
two families of proteins involved in the IFN signaling
pathway.
In summary, our results expand the role of LMP-1 as a
pleiotropic molecule in effecting deregulation of cellular
genes. LMP-1 is now presented as a stimulator of STAT-1,
-2, and -3 in EBV-infected cells, and NF-nB is an essential
factor for this induction. In addition, the expression of
STAT-1 is associated with immortalization and transforma-
tion of human lymphocytes and lymphoblastoid cell lines.Materials and methods
Cells, plasmids, and antibodies
DG75 is an EBV-negative Burkitt’s lymphoma (BL) cell
line (Ben-Bassat et al., 1977). Akata, Eli-BL, Rael, Sav I,
Sav III, P3HR-1, Jijoye, and Raji are all EBV-positive BL
lines (Adldinger et al., 1985; Calender et al., 1987; Klein et
al., 1972; Ragona et al., 1980; Rooney et al., 1986; Takada,
1984). LCC-1 (gift of Dr. Richard Longnecker) and CBC/
B95-8 are EBV-transformed lymphoblastoid cell lines
(LCL) (Pagano et al., 1992). BL41-P3HR1 and BL41-
B95-8 are cell lines converted by infection of EBV-negative
BL41 BL cells with the two different EBV strains (Calender
et al., 1987). Four newly transformed LCLs (LCL-1, -2, -3,
and -4) are gifts from Dr. Kenneth Izumi at the University of
Texas at San Antonio. All cells were maintained in RPMI-
1640 plus 10% FBS. The fresh blood was purchased from
local Red Cross station. The CD19-positive primary B cells
were isolated from fresh PBMC by the use of CD-19
antibody conjugated to magnetic beads according to the
manufacturer’s recommendation (Dynal, Inc.). The method
was used successfully, and the cells isolated were infectable
by EBV (Sinclair et al., 1994, 1995).
pcDNA/CD4, pcLMP1, the mutant LMP-1 plasmids
(LMP-PQAA, LMP-IID, and LMP-DM), EBNA-2 expres-
sion plasmid, and NF-nB reporter constructs were all
described before (Sung et al., 1991; Zhang and Pagano,
1997, 2000, 2001; Zhang et al., 2001). STAT-1 and STAT-3
expression plasmids were gifts from Dr. James Darnell and
Dr. Rolf de Groot, respectively. STAT-2 cDNAwas from Dr.
James Darnell, and the expression plasmid was constructed
in pcDNA-3 vector at KpnI and XbaI sites. Dominant-
negative mutants (DN) for TRAFs (TRAF-1DN, TRAF-
2DN, TRAF-3DN, and TRAF-5DN ), AP-1DN, and janus
kinase 3 (JAK3) DN were described previously (Zhang etal., 2001). The pQ-luc reporter construct has been described
(Davenport and Pagano, 1999).
LMP-1 monoclonal antibody (CS1-4) and EBNA2 spe-
cific antibody (PE2) were purchased from Dako. STAT-1
(sc-417, sc-591), STAT-2 (sc-1668), STAT-3 (sc-482), and
STAT-5A (sc-1081) antibodies were purchased from Santa
Cruz. Phospho-STAT-3-specific (Tyr-705; #9131) and phos-
pho-STAT-5-specific (#9351) antibodies were from Cell
Signaling Technology. Phospho-Ser-727 STAT-1 antibody
(#06-802) and Phospho-Tyr-701 STAT-1 antibody (06-657)
were from Upstate Biotechnology. Tubulin antibody was
from Sigma. ISG-15 antibody was the gift of Dr. Ernest
Borden. Interferon a (IFN-a) was from Hoffmann La
Roche.
Western blot analysis with enhanced chemiluminescence
(ECL)
Separation of proteins on SDS-PAGE followed standard
methods. After the proteins were transferred to a nitrocel-
lulose or Immobilon membrane, the membrane was blocked
with 5% non-fat dry milk in TBST (50 mM Tris pH 7.5, 200
mM NaCl, 0.05% Tween-20) at room temperature for 10
min. It was then washed briefly with water and incubated
with a primary antibody in 5% milk in TBST for 1–2 h at
room temperature, or overnight at 4 jC. After washing with
TBST for 10 min three times, the membrane was incubated
with the secondary antibody at room temperature for 1 h. It
was then washed three times with TBST as before, treated
with ECL (Amersham) or SuperSignal (Pierce) detection
reagents, and exposed to Kodak XAR-5 film.
Transient transfection, chloramphenicol acetyltransferase
(CAT) assays, and isolation of transfected cells
107 cells in 0.5 ml medium were used for transfection
with the use of a BioRad Gene Pulser (320 Volts and 925
AF). Two days after transfection, cells were collected for
reporter assay or for isolation of transfected cells. The
luciferase and h-galactosidase assays were essentially the
same as described (Zhang et al., 2001).
For isolation of transfected cells, enrichment for CD-4-
positive cells was performed with the use of anti-CD-4-
antibody conjugated to magnetic beads according to the
manufacturer’s recommendation (Dynal) as described be-
fore (Zhang and Pagano, 1999, 2000, 2001; Zhang et al.,
2001). The isolated cells were used for the extraction of total
RNA with the use of RNase Total RNA Isolation Kit
(Qiagen) or for Western blot analysis.
RNA extraction and RNase Protection Assays (RPA)
RPA was performed with total RNA with the use of the
RNase Protection Kit II (Ambion, Inc.). The hybridization
temperature was 42 jC. The human STAT probe set was
purchased from Pharmingen (hSTAT Multi-Probe Template
L. Zhang et al. / Virology 323 (2004) 141–152150Set, cat# 558834). The probes were generated with the use
of T7 RNA polymerase. RPA autoradiography was analyzed
with the Syngene Gene Genius Bioimaging System.Acknowledgments
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